Cellect Biotechnology Ltd. (APOP) EPS Estimated At $-0.30

May 17, 2018 - By Migdalia James

Analysts expect Cellect Biotechnology Ltd. (NASDAQ:APOP) to report $-0.30 EPS on June, 4.They anticipate $0.26 EPS change or 650.00 % from last quarter’s $-0.04 EPS. After having $-0.16 EPS previously, Cellect Biotechnology Ltd.’s analysts see 87.50 % EPS growth. The stock increased 0.28% or $0.02 during the last trading session, reaching $7.13. About 17,074 shares traded. Cellect Biotechnology Ltd. (NASDAQ:APOP) has declined 42.02% since May 17, 2017 and is downtrending. It has underperformed by 53.57% the S&P500.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. The company has market cap of $46.41 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.